News – Page 972 – Endpoints News

The Fort Dix redemption: Martin Shkreli’s contraband cell phones, new biotech schemes and fresh social media infamy

7 years ago

Key positive data on monthly HIV regimen offer hope for patients saddled with standard daily pills

7 years ago

FDA reverses course, decides not to add suffixes to older biologics’ nonproprietary names

7 years ago

'We can't': Jeff Leiden stands his ground as MPs grill Vertex on pricing disagreement with NHS

7 years ago

Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some ...

7 years ago

Brent Saunders’ team gets hit with a PhIII disaster — and a growing mob of Allergan critics seizes the moment

7 years ago

FDA pins another 'breakthrough' badge on AbbVie's venetoclax; Express Scripts bats back at drugmakers on pricing

7 years ago

Jeff Marrazzo sparked a bidding war for Spark that spurred a thrifty Roche CEO to seal the winning deal with a ...

7 years ago

Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut

7 years ago

CAR-T shows promise for lupus in mouse study — will it inspire hope in a beleaguered field?

7 years ago

How do you replace a rock star like Scott Gottlieb at the FDA? Maybe you can't

7 years ago

Atul Gawande takes aim at surging prescription drug costs as chief of cryptic Buffett-Bezos-Dimon venture now ...

7 years ago

Allergan’s $560M buyout deal just led to a PhIII debacle as another depression drug goes down to bitter defeat

7 years ago

Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene ...

7 years ago

From dinner in Munich to $5.85 a share, Immune Design execs pushed for every penny they could get from the Merck ...

7 years ago

French VC Seventure focuses second fund on fertile microbiome field — targets €200M-plus

7 years ago

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

7 years ago

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

7 years ago

Vertex's new dilemma: With more positive PhIII data on hand, which of their promising combos should go to the FDA, ...

7 years ago

As opposition mounts against Celgene deal, Bristol-Myers tells shareholders the planned buyout is the best bet in a ...

7 years ago

RNAi trailblazer Alnylam posts promising top-line PhIII snapshot for givosiran, but safety issues drag shares down

7 years ago

Gene editing upstart backed by Broad star Feng Zhang nabs $135M, blueprinting a platform biotech for the long haul

7 years ago

J&J wins FDA OK for their nasal spray version of a party drug, now approved for treatment-resistant major depression

7 years ago

Oncology pipeline chief Alessandro Riva joins the exodus at Gilead, heading to helm a biotech spinoff 4 days after ...

7 years ago

First page Previous page 969 970 971972973 974 975 Next page Last page